Stockscreener 앱 받기
0.6042
15.44%
0.0747
Outlook Therapeutics Inc 주식(OTLK)의 최신 뉴스
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know - TradingView — Track All Markets
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy By Investing.com - Investing.com Canada
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy - Investing.com
Largest borrow rate increases among liquid names - TipRanks
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - Quiver Quantitative
FDA rejects Outlook Therapeutics' third BLA submission of bevacizumab for wet AMD - Eyes On Eyecare
Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright - Investing.com Canada
Chardan Adjusts Price Target on Outlook Therapeutics to $1 From $3, Maintains Neutral Rating - marketscreener.com
OTLK: Chardan Capital Lowers Price Target, Maintains Neutral Rat - GuruFocus
What analysts say about Outlook Therapeutics Inc stockFlag and Pennant Patterns & Double Or Triple Wealth - earlytimes.in
Indegene Limited Included in Top Momentum ScanPortfolio Risk Assessment & Small Investment Big Gains - earlytimes.in
The Narrowing Pathway for Biotech Securities Fraud Claims: Lessons from Outlook Therapeutics - TipRanks
A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares - Stocktwits
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Lifecore Biomedical (LFCR) - The Globe and Mail
Outlook Therapeutics price target lowered to $1 from $3 at Chardan - TipRanks
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset - MSN
Outlook Therapeutics plunges 60% as FDA denies Lytenava approval | Tap to know more | Inshorts - Inshorts
Outlook Therapeutics price target lowered to 50c from $1 at H.C. Wainwright - TipRanks
Missed window? A third CRL sinks Outlook’s ONS-5010 - BioWorld MedTech
Outlook Left Adrift With Another FDA Rejection For Lytenava - Citeline News & Insights
OTLK: HC Wainwright Maintains Neutral Rating, Lowers Price Targe - GuruFocus
What to keep an eye on in 2026 - Eyes On Eyecare
Regulatory tracker: Outlook Therapeutics' ophthalmic bevacizumab hit with another FDA rejection - Fierce Pharma
Outlook Therapeutics shares plunge 61.4% after US FDA declines to approve eye disease drug - marketscreener.com
What analysts say about Outlook Therapeutics Inc 41ON stockSector Leadership Analysis & Small Investment Big Gains - earlytimes.in
Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again - Sahm
Why Is Outlook Therapeutics Stock Sinking Friday?Outlook Therapeutics (NASDAQ:OTLK) - Benzinga
FDA Issues New Setback for Outlook Therapeutics’ LYTENAVA - TipRanks
Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Outlook Therapeutics Receives FDA Complete Response Letter for ONS-5010 - TradingView — Track All Markets
Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks - Yahoo Finance
Why is Outlook Therapeutics (OTLK) Stock Down 61% in Pre-Market Trading? - TipRanks
Outlook Therapeutics plunges after FDA rejects eye drug for third time - TradingView — Track All Markets
Outlook Therapeutics plunges after rejection from the FDA - medwatch.com
Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In Focus - Benzinga
Outlook Therapeutics shares plunge 61.5% premarket after US FDA declines to approve eye disease drug - marketscreener.com
Outlook Therapeutics receives FDA response on ONS-5010 for wet AMD - Pharmaceutical Technology
VIX Spike: Can Outlook Therapeutics Inc. (41ON) stock resist broad market declines - moha.gov.vn
Apple, Taiwan Semiconductor Manufacturing And 3 Stocks To Watch Heading Into Friday - Benzinga
FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present form - Yahoo Finance
Key facts: FDA Rejects Outlook Therapeutics' Lytenava; ONS-5010 Denied Again - TradingView — Track All Markets
Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD - ts2.tech
US FDA declines to approve Outlook Therapeutics’ eye disease drug - wibqam.com
Outlook Therapeutics Shares Sink After FDA Issues Another CRL On Wet AMD Therapy - Nasdaq
FDA rejects Outlook Therapeutics’ ONS-5010 eye treatment application By Investing.com - Investing.com Nigeria
Breaking news: FDA sends CRL to Outlook Therapeutics for ONS-5010 resubmission - Optometry Times
Outlook Therapeutics provides regulatory update on U.S. FDA review of Lytenava - marketscreener.com
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA - Ophthalmology Times
US FDA declines to approve Outlook's eye disease drug for second time in 2025 - Reuters
Outlook Therapeutics slides after US FDA declines its eye disease drug - TradingView — Track All Markets
FDA rejects Outlook Therapeutics’ ONS-5010 eye treatment application - Investing.com India
Outlook Therapeutics (OTLK) Shares Plunge After FDA Setback - GuruFocus
Outlook Therapeutics (OTLK) Faces FDA Setback for Wet AMD Treatm - GuruFocus
Outlook Therapeutics Faces Challenges Amid Market Dynamics - StocksToTrade
Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date - ts2.tech
Outlook Therapeutics stock plunges after FDA rejects wet AMD drug application - Investing.com Canada
Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision - ts2.tech
Outlook Therapeutics Says FDA Didn't Approve Macular Degeneration Drug Application - marketscreener.com
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset (NASDAQ:OTLK) - Seeking Alpha
0.93%
0.16%
자본화:
|
볼륨(24시간):